Revision History

1 revisions for "The GLP-1 Lottery: Why Ozempic Fails One in Four Patients — and What Science Is Finally Learning About It"

Anonymousabout 3 hours ago

Two major studies published in April 2026 — one from Stanford/ETH Zurich on PAM enzyme variants, another from 23andMe on GLP1R gene polymorphisms — offer the first concrete genetic explanations for why up to 23% of patients on semaglutide drugs like Ozempic and Wegovy see minimal weight loss. But skeptics argue that adherence, gut microbiome variation, and appetite phenotypes may explain more non-response than genetics, and a validated companion diagnostic test remains years away.